

ENABLING MORE INFORMED TREATMENT DECISIONS.
PROMOTING PERSONALIZED PATIENT CARE.



Innovative SOLUTIONS for
COMPREHENSIVE
Urological Cancer Care





Deep urology expertise combined with unrivaled solutions through a complementary mix of traditional and world-class proprietary products

Our comprehensive approach gives physicians and their patients better information to make more informed treatment decisions, leading to higher quality of life and improved standard of care.

- Advanced diagnostic and prognostic solutions
- Superior clinical expertise
- Enhanced specimen security
- Easy-to-interpret diagnostic reports
- Trusted second-opinion services
 - Dedicated customer support
 - Knowledgeable billing and insurance specialists
 - Customized business solutions

Addressing the **full urologic cancer care** continuum



An advanced proteomic prognostic test developed specifically for prostate cancer, using sophisticated automated image recognition technology to predict the risk of aggressive disease in patients with Gleason Scores of 3+3 and 3+4.



The first urine-based molecular test that delivers confidence to make informed repeat biopsy decisions.

PTEN/TEMPRESS2:ERG

Molecular testing that predicts the disease aggressiveness of HGPIN/atypical or low Gleason Score 6 and 7 prostate cancer patients.

Histology

Our histology diagnostic services include expert prostate and bladder biopsy analysis as well as supporting services and examinations.

Cytology

Our cytology diagnostic services provide superior specificity in the diagnosis of bladder cancer.

FISH

FISH, or fluorescence in situ hybridization — a diagnostic tool that may help confirm cytology results, monitor bladder cancer recurrence, and measure treatment response.

A first-of-its-kind protein-based prognostic test for prostate cancer



Predict cancer aggressiveness in patients with biopsy Gleason Scores of **3+3** and **3+4**.

- ✓ Provides a **personalized prediction** that the cancer can be managed without aggressive treatment, or an indication that aggressive therapy may be appropriate
- ✓ Powerful, **independent** risk predictor for prostate cancer
- ✓ **Objective** and fully reproducible
- ✓ Addresses tumor heterogeneity and biopsy sampling error
- ✓ **Cutting-edge**, automated image recognition technology
- ✓ Completely **standalone result** not dependent upon other risk factors; can be combined with NCCN risk category for additional information
- ✓ **Intuitive report**, allowing for productive discussion with your patient

Utilizing automated image analysis technology that identifies tumor and benign tissues, ProMark measures the quantitative expression levels of eight protein biomarkers, **resistant to sampling variability and pathologist discordance**, that individually correlate with tumor aggressiveness and together predict your individual patient's risk of aggressive disease.

Unlike genomic-based tests that require pathologists to indicate the areas of tumors, ProMark technology allows for analysis of proteins, a more direct reflection of biologic activity, **directly from the cancerous regions of interest**. There is no need for micro dissection and homogenization of tissue.



Confirm negative biopsies with **CONFIDENCE**



- The first urine-based molecular test that delivers confidence to **make informed repeat biopsy decisions**
- **HIGHLY SPECIFIC** – indicates a cancer specificity lacking with PSA alone
- **EASY TO USE** – utilizes a FIRST-CATCH urine sample post-DRE
- Extensive **CLINICAL DATA**
- FDA approved
- Included in the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection



BETTER INFORMATION promotes confident decisions.

Unlike PSA, PCA3 is not influenced by benign hyperplasia (BPH), prostatitis, medical procedures, or injury.


All insurance coverage accepted.

The ProgenSA® PCA3 assay is provided to Metamark by Hologic.



Positive biopsy results by PCA3 Score with 95% confidence limits¹

The dashed line represents predicted probability of positive biopsy from a logistic regression model. Ranges represent quartiles of the PCA3 Score distribution.



- As the PCA3 Score increases, the likelihood for positive biopsy increases.
- As the PCA3 Score decreases, the likelihood for positive biopsy decreases.

Improve your biopsy decisions.

Reduce the number of unnecessary repeat biopsies.

1. Gittleman, Marc C, et al. PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study. The Journal of Urology, Vol. 190, (2013): 64-69.

PTEN/TMPRSS2:ERG

For atypical/HGPIN patients, and those with low Gleason Scores 6 and 7, PTEN/TMPRSS2:ERG molecular testing can help predict prostate cancer aggressiveness, providing additional information to **make a more informed treatment decision.**

- ▶ Anticipate prostate cancer aggressiveness, confirming genetic changes before the cancer develops and metastasizes
- ▶ Differentiate patients requiring aggressive treatment from those appropriate for active surveillance
- ▶ Determine suitable monitoring intervals and build customized treatment plans

Appropriate treatment decisions
require individual patient assessment.

**Reflex to PTEN and
ERG for your atypical
and HGPIN patients.**

FISH Molecular Cytology

Add an extra measure of certainty.

- ▶ Screen high-risk patients
- ▶ Monitor bladder cancer recurrence
- ▶ Confirm cytology results
- ▶ Measure treatment response

FISH (fluorescence in situ hybridization) can:

- ✔ **Anticipate cancer**, confirming genetic changes prior to tumors being visible on cystoscopy
- ✔ Detect cancers **beyond the view** of the cystoscope, including in the upper tract, pelvis, and prostatic urethra
- ✔ **Detect and confirm** occult diseases such as CIS which may lie flat against the bladder wall
- ✔ Provide near-equivalent specificity to traditional cytology, however with much **greater sensitivity**

Detect and treat bladder cancer earlier with FISH Molecular Cytology as an adjunct to cystoscopy.



The biopsy

You need fast and accurate results you can trust. Our expert uropathologists will carefully analyze your specimens, and deliver the results within a detailed biopsy pathology report.

Metamark will work with you to determine and provide the biopsy kit you need to fit your specific practice needs.

- ✓ Easy to use
- ✓ Dependable, detailed results
- ✓ Enhanced security, with unique two-dimensional bar-coding
- ✓ Available in a range of specimen vial sizes



Take advantage of our streamlined pathology collection process.

SimplifID™

SimplifID™ is our patented, next-generation prostate biopsy kit with cassettes.

Its all-in-one design is easy-to-use, and all components are pre-labeled with 2D barcodes to continually link the patient and specimen, ensuring specimen security and accurate patient identification from procedure to report. SimplifID includes everything you need for prostate biopsy specimen collection and send-out:

- ✔ Cassettes
- ✔ Formalin Jars
- ✔ Test Requisition
- ✔ Biohazard Bag
- ✔ Shipping Lab Pack with Pre-Addressed Label



No other supplies or labeling is required,
and SimplifID is one-patient-per-box,
saving you time and minimizing
opportunity for error.

Advanced diagnostic and prognostic solutions for urological cancer care, backed by superior clinical expertise and the highest level of customer support



Learn more about our high-quality portfolio of products and services, tailored to meet your individual needs.



Contact your local
Metamark representative



Visit
metamarkgenetics.com



Call Metamark
Client Services at
877-743-3338